TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10412846

Group type: EXPERIMENTAL
Intervention: Rescored plaque index from previously recorded plaque areas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Original plaque index scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plaque area measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Original plaque index derived from buccal surfaces of all teeth
Number of subjects: 0
Study: 7539609

Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2110425

Group type: EXPERIMENTAL
Intervention: Midazolam (0.16 mg/kg) with flumazenil (0.55 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol (1.50 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam (0.16 mg/kg)
Number of subjects: 60
Study: 383023

Group type: EXPERIMENTAL
Intervention: Nalorphine IV
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Naloxone IV (0.01 mg/kg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Naloxone IV (0.02 mg/kg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no antagonist)
Number of subjects: 85
Study: 30600153

Group type: EXPERIMENTAL
Intervention: Visual Decalogue aid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overall educational intervention
Number of subjects: 100
Study: 25775165

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle arm
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin arm
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Placebo arm
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Normalization of FPG
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 3234
Study: 23389823

Group type: EXPERIMENTAL
Intervention: Nonanalytic group (25 participants)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Analytic group (24 participants)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 49
Study: 21551966

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy using dual-agent injection of blue dye and radioactive colloid
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy without axillary lymph node dissection
Number of subjects: 253
Study: 19873708

Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted partial-superficial parotidectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional partial-superficial parotidectomy
Number of subjects: 38
Study: 17442659

Group type: EXPERIMENTAL
Intervention: Ibandronate 50 mg/day
Number of subjects: 275

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg every 4 weeks
Number of subjects: 275
Study: 14696020

Group type: EXPERIMENTAL
Intervention: Fexofenadine (120 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Olopatadine (10 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: d-chlorpheniramine (4 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10777122

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 36
Study: 8639180

Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-10 and IL-4 (combination)
Number of subjects: 0
Study: 1600042

Group type: EXPERIMENTAL
Intervention: Cisapride 2.5 mg three times daily for 7 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cisapride 2.5 mg plus Domperidone 10 mg three times daily for 7 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cisapride plus Placebo
Number of subjects: 25
Study: 3917606

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 8

Group type: COMPARATOR
Intervention: Combined chlorpheniramine and cimetidine
Number of subjects: 8
Study: 31251375

Group type: EXPERIMENTAL
Intervention: Thirdhand smoke (THS) exposure for 3 hours
Number of subjects: 4

Group type: COMPARATOR
Intervention: Clean air exposure for 3 hours
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: THS exposure
Number of subjects: 4
Study: 29428919

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care with Music therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Music therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 200
Study: 25917211

Group type: EXPERIMENTAL
Intervention: Functional foot orthoses (FFOs)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham control orthosis
Number of subjects: 37
Study: 24658964

Group type: COMPARATOR
Intervention: Imatinib 400 mg/day (IM400)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg/day (IM800)
Number of subjects: 784
Study: 22440975

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg dexamphetamine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20075953

Group type: EXPERIMENTAL
Intervention: Novel vaccine adjuvant system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HBV vaccine
Number of subjects: 0
Study: 17914132

Group type: EXPERIMENTAL
Intervention: Proprietary formulation of Camellia sinensis (green tea) capsules, twice a day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules, twice a day for 3 months
Number of subjects: 0
Study: 16168327

Group type: EXPERIMENTAL
Intervention: facemask with palatal expansion
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: facemask without palatal expansion
Number of subjects: 46

Group type: COMPARATOR
Intervention: observation
Number of subjects: 46
Study: 12151613

Group type: EXPERIMENTAL
Intervention: Skin care programme (educational programme and skin care policy)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 375
Study: 9831059

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Aceclofenac 150 mg
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 7924164

Group type: EXPERIMENTAL
Intervention: acute hyperinsulinaemic hypoglycaemia (60 m-units min-1 m-2, 2.5 mmol/l)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: prolonged hyperinsulinaemic hypoglycaemia (60 m-units min-1 m-2, 2.5 mmol/l)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: euglycaemia (4.5 mmol/l)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo control (saline)
Number of subjects: 10
Study: 2506998

Group type: EXPERIMENTAL
Intervention: 125I-NovoSol Basal
Number of subjects: 8

Group type: COMPARATOR
Intervention: 125I-Ultratard HM
Number of subjects: 8
Study: 54631

Group type: EXPERIMENTAL
Intervention: Influenza-B vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza-A vaccine (A/Hong Kong)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural infection (Influenza-A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza-B H.I. antibody
Number of subjects: 0
Study: 31372917

Group type: EXPERIMENTAL
Intervention: CX-DZ-II intelligent electroacupuncture instrument
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pre-existing electroacupuncture instrument
Number of subjects: 160
Study: 31779179

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium fortified yogurt (400 IU of vitamin D3 and 800 mg calcium daily for 3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-fortified yogurt (300 mg calcium, no vitamin D3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium fortified yogurt
Number of subjects: 40
Study: 30362038

Group type: EXPERIMENTAL
Intervention: High food availability
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Normal food availability
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low food availability
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hypoxic conditions (low dissolved oxygen)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tail muscle tissue
Number of subjects: 48
Study: 27670603

Group type: EXPERIMENTAL
Intervention: Amoxicillin group
Number of subjects: 312

Group type: COMPARATOR
Intervention: Tetracycline group
Number of subjects: 312
Study: 24120589

Group type: EXPERIMENTAL
Intervention: Autotransfusion drain
Number of subjects: 115

Group type: COMPARATOR
Intervention: No drainage system
Number of subjects: 115
Study: 22071502

Group type: EXPERIMENTAL
Intervention: Variable Practice (VP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Constant Practice (CP) at 30% of maximum speed
Number of subjects: 33

Group type: COMPARATOR
Intervention: Constant Practice (CP) at 55% of maximum speed
Number of subjects: 33
Study: 19349548

Group type: COMPARATOR
Intervention: Standard regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (IE) over 48 weeks
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Dose-intensified regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (IE) over 30 weeks
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Both regimens (standard and intensified)
Number of subjects: 478
Study: 17764540

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once-daily
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once-daily
Number of subjects: 2076

Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once-daily
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: All groups (Dabigatran 220 mg, Dabigatran 150 mg, Enoxaparin)
Number of subjects: 2076
Study: 15139393

Group type: EXPERIMENTAL
Intervention: Pork meat diet (170 g pig meat/10 MJ per day, 106 +/- 13 microg Se/d)
Number of subjects: 12
Study: 11456384

Group type: EXPERIMENTAL
Intervention: Enriched n-6 polyunsaturated fat diet (9.2% energy from linoleic acid) for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: High monounsaturated or saturated fat diet for 8 weeks (control)
Number of subjects: 26
Study: 9919621

Group type: EXPERIMENTAL
Intervention: Nicotinic acid supplementation at 0-100 mg/day for 14 weeks
Number of subjects: 21
Study: 7750677

Group type: EXPERIMENTAL
Intervention: Mannitol group (n = 20) treated by whole gut irrigation with a 5 L solution containing 40 g/L of mannitol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mannitol group (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 3281488

Group type: COMPARATOR
Intervention: C25 (25 mg/kg chloroquine over 3 days)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: C50 (50 mg/kg chloroquine over 5 days)
Number of subjects: 138
Study: 1363409

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of hydrocortisone succinate, 100 mg bolus at time 0 followed by 250 mg in 250 ml saline for 120 min
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous infusion of saline, 250 ml
Number of subjects: 5
Study: 408839

Group type: EXPERIMENTAL
Intervention: l-tryptophane 1 g
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: l-tryptophane 3 g
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31259734

Group type: EXPERIMENTAL
Intervention: CYP2C9*2 allelic variant carriers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CYP2C9 *1/*3 or CYP2C9*1/*1 genotype carriers
Number of subjects: 27
Study: 27085364

Group type: EXPERIMENTAL
Intervention: Autologous PRP therapy combined with a rehabilitation programme
Number of subjects: 75

Group type: COMPARATOR
Intervention: Rehabilitation programme only
Number of subjects: 75
Study: 24451919

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 24329929

Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite rinse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water rinse (control)
Number of subjects: 30
Study: 21966999

Group type: EXPERIMENTAL
Intervention: Darbepoetin (300 μg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study: 19363974

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (CS3)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (ADP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: iBond (iB)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 6
Study: 18637458

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free immunosuppression
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Number of subjects: 650
Study: 14688150

Group type: EXPERIMENTAL
Intervention: Estrogen‐progestin treatment (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative reference group in observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHI Study (HRT)
Number of subjects: 0
Study: 11451717

Group type: EXPERIMENTAL
Intervention: 4 g highly concentrated n‐3 fatty acids
Number of subjects: 300

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 300
Study: 9540761

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g every 8 h)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ceftazidime (2 g every 8 h) and Amikacin (15 mg/kg/day)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ceftazidime/Amikacin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 8044157

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 2736055

Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (somatropin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no somatropin)
Number of subjects: 12
Study: 29406463

Group type: EXPERIMENTAL
Intervention: Lopinavir‐based antiretroviral therapy (ART)
Number of subjects: 161
Study: 27422740

Group type: EXPERIMENTAL
Intervention: Vedolizumab (0.2, 0.5, 2.0, 6.0, or 10.0 mg/kg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23689561

Group type: EXPERIMENTAL
Intervention: Calcium co-ingestion (15 mg/kg body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control meal (3 mg/kg body mass)
Number of subjects: 10
Study: 22275153

Group type: EXPERIMENTAL
Intervention: Rectal distension
Number of subjects: 26

Group type: COMPARATOR
Intervention: No rectal distension (control)
Number of subjects: 26
Study: 20487528

Group type: EXPERIMENTAL
Intervention: Intensive educational intervention consisting of group sessions with standardised information about OAC therapy, lifestyle interactions, and INR monitoring.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 200
Study: 18779274

Group type: EXPERIMENTAL
Intervention: Milk intervention (3 servings/day, approximately 200 g per serving)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no change in milk consumption)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Milk intervention
Number of subjects: 98
Study: 15759594

Group type: EXPERIMENTAL
Intervention: Early-onset/increasers trajectory of aggression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-persistent trajectory of aggression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable low levels of aggression
Number of subjects: 0
Study: 12422106

Group type: EXPERIMENTAL
Intervention: Upper quartile of BMI (>30 kg/m(2))
Number of subjects: 104

Group type: COMPARATOR
Intervention: Lower BMI (not specified)
Number of subjects: 104
Study: 10365534

Group type: EXPERIMENTAL
Intervention: OHT recipients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (sedentary healthy men)
Number of subjects: 17
Study: 8779381

Group type: EXPERIMENTAL
Intervention: Radial pulse identification
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Carotid pulse identification
Number of subjects: 554

Group type: COMPARATOR
Intervention: Airway management (laryngeal mask airway or tracheal tube)
Number of subjects: 554
Study: 1516506

Group type: EXPERIMENTAL
Intervention: Single individual session
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 12-week behavior-oriented diabetes education and weight control group intervention
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Group intervention plus six individual follow-up sessions
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Diabetes education-weight reduction intervention
Number of subjects: 82
Study: 6372925

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (including antidepressant medication)
Number of subjects: 0
Study: 29573098

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 116
Study: 27608611

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over the supplementary motor area
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 22
Study: 24576532

Group type: EXPERIMENTAL
Intervention: paliperidone extended-release (3-12 mg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: paliperidone extended-release
Number of subjects: 136

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 136
Study: 23018470

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 179
Study: 20357160

Group type: EXPERIMENTAL
Intervention: Sugammadex (2, 4, and 16 mg/kg)
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Sugammadex
Number of subjects: 1321
Study: 19101896

Group type: EXPERIMENTAL
Intervention: Petroleum jelly applied after each diaper change for 6 months
Number of subjects: 394
Study: 16098297

Group type: EXPERIMENTAL
Intervention: Left bundle branch block (n = 48)
Number of subjects: 3053

Group type: EXPERIMENTAL
Intervention: Right bundle branch block (n = 95)
Number of subjects: 3053

Group type: COMPARATOR
Intervention: No bundle branch block (n = 2910)
Number of subjects: 3053
Study: 12394420

Group type: EXPERIMENTAL
Intervention: Citalopram (serotonergic challenge)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopaminergic challenge)
Number of subjects: 36
Study: 10068597

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 1500
Study: 7774513

Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg twice daily, initiated post-operatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily starting preoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study: 2200994

Group type: EXPERIMENTAL
Intervention: Cefaclor (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 1)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 2)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 2 divided doses (group 3)
Number of subjects: 73
Study: 6269247

Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study: 30819486

Group type: EXPERIMENTAL
Intervention: Palmar warming with a warm, commercially available, air-activated heat pack
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group with a deactivated heat pack
Number of subjects: 45
Study: 27866188

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) placement
Number of subjects: 36
Study: 25678316

Group type: EXPERIMENTAL
Intervention: Couple-focused telephone-counseling program (up to 4 postnatal counseling calls using motivational interviewing)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 250
Study: 23117350

Group type: EXPERIMENTAL
Intervention: Social support (social integration, received social support, and negative social interactions)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies Depression Scale
Number of subjects: 173
Study: 20825401

Group type: EXPERIMENTAL
Intervention: Distraction during the third task (answering questions about a medical case)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 86
Study: 20681373

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repairs (EVARs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall trend in EVARs
Number of subjects: 0
Study: 17389151

Group type: EXPERIMENTAL
Intervention: Telmisartan and hydrochlorothiazide combination therapy, dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but implied as standard treatment or placebo.
Number of subjects: 0
Study: 15625792

Group type: EXPERIMENTAL
Intervention: Suppression group (n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Focalization group (n = 30)
Number of subjects: 61
Study: 11208684

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator therapy
Number of subjects: 440

Group type: COMPARATOR
Intervention: Unstable VT (control group)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Adjusted for baseline and treatment differences
Number of subjects: 440
Study: 9686850

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% eye drops
Number of subjects: 43

Group type: COMPARATOR
Intervention: Flurbiprofen 0.03% eye drops
Number of subjects: 43
Study: 9453072

Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of apomorphine at 250 microA.cm‐2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of apomorphine at 375 microA.cm‐2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Passive application of apomorphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Current delivery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mathematical deconvolution of profiles
Number of subjects: 10